These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 24048407)

  • 1. Importance of the newer generations of antipsychotics in reducing schizophrenia hospitalization rates.
    Jukić V; Savić A; Herceg M
    Psychiatr Danub; 2013 Sep; 25(3):329-33. PubMed ID: 24048407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
    Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E
    J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between early subjective response to antipsychotics and the number of hospitalizations and hospitalization days in a period of 10-11 years in schizophrenia patients.
    Murawiec S; Boutros NN
    Neuropsychobiology; 2012; 66(2):120-5. PubMed ID: 22814250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral.
    Offord S; Wong B; Mirski D; Baker RA; Lin J
    J Med Econ; 2013; 16(2):231-9. PubMed ID: 23163287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Persons suffering from schizophrenia and relapses].
    Passerieux C; Caroli F; Giraud-Baro E
    Encephale; 2009 Dec; 35(6):586-94. PubMed ID: 20004290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey.
    Kennedy J; Tien YY; Cohen LJ; Sclar DA; Liu D; Blodgett EG; Engle J
    Clin Ther; 2009 Dec; 31(12):2931-9. PubMed ID: 20110033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospitalisation risks in the treatment of schizophrenia in a Medicaid population: comparison of antipsychotic medications.
    Gianfrancesco F; Wang RH; Pesa J; Rajagopalan K
    Int J Clin Pract; 2006 Nov; 60(11):1419-24. PubMed ID: 17073838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the pharmacotherapy of schizophrenia.
    Borison RL
    Harv Rev Psychiatry; 1997; 4(5):255-71. PubMed ID: 9385002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other.
    Fleischhacker WW; Widschwendter CG
    Curr Opin Psychiatry; 2006 Mar; 19(2):128-34. PubMed ID: 16612191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choice of maintenance medication for schizophrenia.
    Davis JM; Chen N
    J Clin Psychiatry; 2003; 64 Suppl 16():24-33. PubMed ID: 14680416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.